levonorgestrel
Levonorgestrel is a hormonal medication used in a number of birth control methods. It is combined with an estrogen to make combination birth control pills. As an emergency birth control, sold under the brand names Plan B One-Step and Julie, among others, it is useful within 72 hours of unprotected sex. The more time that has passed since sex, the less effective the medication becomes. Levonorgestrel works by preventing or delaying ovulation so an egg cannot be released. The dosage used for emergency contraception is ineffective when ovulation has already occurred, and has been found to have no effect on implantation. It decreases the chances of pregnancy by 57–93%. In an intrauterine device (IUD), such as Mirena among others, it is effective for the long-term prevention of pregnancy. A levonorgestrel-releasing implant is also available in some countries. — Wikipedia
Clinical trial activity
86 trials · 89 clinical orgs · 0 marketing orgs
Earliest trial started Apr 1, 2012 (NCT01601366)
Timeline
Indications
Approved for
Studied for
- Adenomyosis · Phase 2
- Affect · Phase 4
- Amenorrhea · Phase 2
- Anti-Infective Agents · Phase 1
- Anti-Retroviral Agents · Phase 2
- Art · Phase 4
- Biological Availability · Phase 1
- Bone Density · Phase 2
- Breast Feeding · Phase 4
- Contraception · Phase 4
- Contraception Behavior · Phase 1
- Contraception, Postcoital · Phase 4
- Contraceptive Agents · Phase 4
- Dermatitis, Atopic · Phase 1
- Diabetes Mellitus, Type 2 · Phase 1
- Drug Interactions · Phase 1
- Endometrial Hyperplasia · Phase 3
- Endometrial Neoplasms · Phase 2
- Endometriosis · Phase 3
- Fertilization in Vitro · Phase 2/Phase 3
- Healthy Volunteers · Phase 2
- Hematologic Neoplasms · Phase 1
- Hemorrhage · Phase 1/Phase 2
- Hepatitis B, Chronic · Phase 1
- HIV · Phase 4
- HIV Infections · Phase 2
- Hypogonadism · Phase 4
- Inflammation · Phase 4
- Leiomyoma · Phase 4
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Men · Phase 2
- Menorrhagia · Phase 4
- Menstrual Cycle · Phase 2
- Migraine Disorders · Phase 3
- Multiple Sclerosis · Phase 1
- Musculoskeletal Diseases · Phase 4
- Neoplasms · Phase 1
- Neural Analyzers · Phase 4
- Non-alcoholic Fatty Liver Disease · Phase 1
- Obesity · Phase 2/Phase 3
- Pharmacokinetics · Phase 1/Phase 2
- Polycystic Kidney, Autosomal Dominant · Phase 1
- Postpartum Period · Phase 4
- Pre-Exposure Prophylaxis · Phase 1
- Pregnancy · Early Phase 1
- Pregnancy Complications · Phase 3
- Scleroderma, Systemic · Phase 1
- Therapeutic Equivalency · Phase 1
- Tuberculosis · Phase 2
- Uterine Diseases · Phase 4
- Women · Phase 1
Mechanism of action
- Progesterone receptorAGONIST
PGR agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLevonorgestrel ↗
Also known as
- levocept
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07222228 | Phase 2 | Apr 1, 2026 | National Institutes of Health (NIH), Premier Research Group |
| NCT07190430 | Phase 1 | Oct 3, 2025 | Pfizer |
| NCT07074327 | Phase 1 | Jul 11, 2025 | Vertex |
| NCT07010146 | Phase 2 | Jul 1, 2025 | National Institutes of Health (NIH), University of Virginia |
| NCT06942936 | Phase 1 | May 28, 2025 | AstraZeneca, Parexel |
| NCT06799884 | Phase 1 | Jan 18, 2025 | Idorsia Pharmaceuticals Ltd. |
| NCT06727734 | Phase 3 | Dec 31, 2024 | The Family Planning Association of Hong Kong, The University of Hong Kong |
| NCT06620939 | N/A | Dec 1, 2024 | Jiao Tong University, Nanjing Medical University |
| NCT06657105 | Phase 1 | Nov 1, 2024 | AstraZeneca |
| NCT06492889 | Phase 2/Phase 3 (Phase 3) | Jul 22, 2024 | Cuidado Integral de la Mujer, Gineclinic, S.C., Gynuity Health Projects |
| NCT06513104 | Phase 1 | Jul 18, 2024 | Novo Nordisk |
| NCT06455969 | Phase 4 | Jul 15, 2024 | United States Army, University of Pittsburgh |
| NCT06461039 | Phase 1 | Jun 14, 2024 | Novo Nordisk |
| NCT06380205 | Phase 1 | May 7, 2024 | Incyte |
| NCT06354257 | Phase 1 | Apr 5, 2024 | GlaxoSmithKline |
| NCT05903131 | Phase 2 | Jan 31, 2024 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT06188026 | Phase 1 | Dec 18, 2023 | Novo Nordisk |
| NCT05896384 | Phase 1 | Dec 7, 2023 | Boehringer Ingelheim |
| NCT06162611 | Phase 4 | Nov 6, 2023 | Planned Parenthood, University of Utah |
| NCT06071442 | Phase 1 | Oct 9, 2023 | Alexion |
Organizations
Research & Development (89)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institutes of Health (NIH) | Government | 9 | 0 | 3 | 2017 |
| Pfizer | For profit | 8 | 8 | 1 | 2018 |
| Novo Nordisk | For profit | 4 | 4 | 1 | 2021 |
| AstraZeneca | For profit | 3 | 3 | 1 | 2022 |
| Bayer | For profit | 3 | 3 | 2 | 2017 |
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 2018 |
| CONRAD | For profit | 3 | 2 | 3 | 2017 |
| Grunenthal | For profit | 3 | 3 | 1 | 2019 |
| Health Decisions | For profit | 3 | 3 | 3 | 2018 |
| Johnson and Johnson | For profit | 3 | 3 | 1 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 0 | 3 | 2018 |
| University of Utah | Academic/Hospital | 3 | 2 | 2 | 2016 |
| University of Washington | Academic/Hospital | 3 | 1 | 2 | 2018 |
| Assiut University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Cuidado Integral de la Mujer, Gineclinic, S.C. | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Gynuity Health Projects | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Idorsia Pharmaceuticals Ltd. | For profit | 2 | 2 | 1 | 2020 |
| International Partnership for Microbicides, Inc. | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Kenya Medical Research Institute | Academic/Hospital | 2 | 0 | 2 | 2018 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2022 |